Pemetrexed-induced organizing pneumonia in the treatment of lung adenocarcinoma

Pemetrexed-induced organizing pneumonia in the treatment of lung adenocarcinoma

Bibliographic Details
Main Authors:	N. China-Pereira, S. Campainha, A. Furtado, S. Conde, A. Barroso
Format:	Article
Language:	English
Published:	Elsevier 2017-11-01
Series:	Revista Portuguesa de Pneumologia (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S217351151730132X

Similar Items

Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma
by: L. Yu. Vladimirova, et al.
Published: (2021-03-01)

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
by: Lin Z, et al.
Published: (2017-11-01)

Pemetrexed Alone versus Pemetrexed Combined with Oxaliplatin as Salvage Therapy  in Stage IV Lung Adenocarcinoma
by: Youru LIU, et al.
Published: (2011-09-01)

Pemetrexed inhibits the proliferation of lung adenocarcinoma cell line A549
by: PAN Shan, LIN Kengqiang, CHEN Shuxing
Published: (2023-09-01)

Safety and efficacy of pemetrexed for the treatment of lung adenocarcinoma in patients with various stages of chronic kidney disease
by: Jieun Yang, et al.
Published: (2022-04-01)

Decitabine Sensitizes the Radioresistant Lung Adenocarcinoma to Pemetrexed Through Upregulation of Folate Receptor Alpha
by: Yuqing Wang, et al.
Published: (2021-05-01)

PRL-3 antibody combined with pemetrexed induces apoptosis of human lung adenocarcinoma cell line A549
by: SHENG Xin, LIU Dan, DENG Shu-kai
Published: (2020-05-01)

Clinical case of long-term pemetrexed-based chemotherapy treatment for pulmonary adenocarcinoma (ALA +)
by: A. M. Lozhkina, et al.
Published: (2018-11-01)

Pemetrexed induced pneumonitis
by: Binod Dhakal, et al.
Published: (2011-11-01)

Case report: First case of pemetrexed plus cisplatin-induced immune hemolytic anemia in a patient with lung adenocarcinoma
by: Hongkai Lu, et al.
Published: (2022-08-01)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
by: Goyal Pankaj, et al.
Published: (2016-01-01)

Serum Homocysteine and Vitamin B12 as Biomarkers for Haematological Toxicity in Lung Adenocarcinoma Treated With Pemetrexed
by: Chang Zhi, et al.
Published: (2019-06-01)

Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma
by: Jia-Ni Wang, et al.
Published: (2021-09-01)

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report
by: Linda Sakhri, et al.
Published: (2017-09-01)

Effects of EGFT-TKIs on Sequential Pemetrexed  for Advanced Pulmonary Adenocarcinoma
by: Xiangying WANG, et al.
Published: (2012-05-01)

Efficacy and Toxicity of Maintenance Pemetrexed Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Non-small-cell Non-squamous Carcinoma of the Lung
by: Kim D. H., et al.
Published: (2015-06-01)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
by: Long-Hua Guo, et al.
Published: (2020-09-01)

Ku80 correlates with neoadjuvant chemotherapy resistance in human lung adenocarcinoma, but reduces cisplatin/pemetrexed-induced apoptosis in A549 cells
by: Bin Shang, et al.
Published: (2017-04-01)

Association between the ALK Gene Status and the Efficacy of First-line  Pemetrexed Chemotherapy in Patients with Advanced Lung Adenocarcinoma
by: Mengge CHEN, et al.
Published: (2017-11-01)

Combining a CDK4/6 Inhibitor With Pemetrexed Inhibits Cell Proliferation and Metastasis in Human Lung Adenocarcinoma
by: Yuan Ke, et al.
Published: (2022-05-01)

Targeting mitochondrial one-carbon enzyme MTHFD2 together with pemetrexed confers therapeutic advantages in lung adenocarcinoma
by: Juanfen Mo, et al.
Published: (2022-07-01)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
by: Bo Jia, et al.
Published: (2020-12-01)

Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
by: J Greenhalgh, et al.
Published: (2010-10-01)

Tailoring treatment of nonsmall cell lung cancer by tissue type: role of pemetrexed
by: Steven F Powell, et al.
Published: (2009-06-01)

Treatment of anaplastic lymphoma kinase-positive lung adenocarcinoma with pemetrexed and carboplatin after crizotinib failure and significant liver dysfunction; a case report
by: Oranus Mohammadi, et al.
Published: (2021-01-01)

Prediction of response and adverse drug reaction of pemetrexed plus platinum-based chemotherapy in lung adenocarcinoma by serum metabolomic profiling
by: Wei-Jing Gong, et al.
Published: (2022-05-01)

Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism
by: SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao
Published: (2021-04-01)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
by: Seung Sook Paik, M.D., et al.
Published: (2018-04-01)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
by: Yuan Ying, et al.
Published: (2012-11-01)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
by: Xin Li, et al.
Published: (2021-05-01)

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: N Fleeman, et al.
Published: (2010-05-01)

Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer
by: N Fleeman, et al.
Published: (2010-05-01)

Concomitant lung cancer and interstitial lung disease: A challenge in clinical practice
by: R. Linhas, et al.
Published: (2017-03-01)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
by: Minami S, et al.
Published: (2015-01-01)

Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes
by: Jiun-Long Wang, et al.
Published: (2021-08-01)

Pemetrexed-associated Ischemic Colitis in Nonsmall Cell Lung Cancer
by: Liang Ye, et al.
Published: (2017-01-01)

Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non‐squamous, non‐small cell lung cancer: TORG (thoracic oncology research group) 1321
by: Takashi Kasai, et al.
Published: (2023-07-01)

The efficacy and safety of pemetrexed-based doublet therapy compared to pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer: an updated meta-analysis
by: Zhong AY, et al.
Published: (2015-07-01)

A Case of Posterior Reversible Encephalopathy Syndrome Induced by Cisplatin/Pemetrexed Chemotherapy for Lung Cancer
by: Masashi Ishihara, et al.
Published: (2017-03-01)

Augmented expression of cardiac ankyrin repeat protein is induced by pemetrexed and a possible marker for the pemetrexed resistance in mesothelioma cells
by: Yiyang Qin, et al.
Published: (2017-12-01)